Abstract
Purpose
GSK923295 is an inhibitor of CENP-E, a key cellular protein important in the alignment of chromosomes during mitosis. This was a Phase I, open-label, first-time-in-human, dose-escalation study, to determine the maximum-tolerated dose (MTD), safety, and pharmacokinetics of GSK923295.
Patients and methods
Adult patients with previously treated solid tumors were enrolled in successive cohorts at GSK923295 doses ranging from 10 to 250 mg/m2. GSK923295 was administered by a 1-h intravenous infusion, once weekly for three consecutive weeks, with treatment cycles repeated every 4 weeks.
Results
A total of 39 patients were enrolled. The MTD for GSK923295 was determined to be 190 mg/m2. Observed dose-limiting toxicities (all grade 3) were as follows: fatigue (n = 2, 5%), increased AST (n = 1, 2.5%), hypokalemia (n = 1, 2.5%), and hypoxia (n = 1, 2.5%). Across all doses, fatigue was the most commonly reported drug-related adverse event (n = 13; 33%). Gastrointestinal toxicities of diarrhea (n = 12, 31%), nausea (n = 8, 21%), and vomiting (n = 7, 18%) were generally mild. Frequency of neutropenia was low (13%). There were two reports of neuropathy and no reports of mucositis or alopecia. GSK923295 exhibited dose-proportional pharmacokinetics from 10 to 250 mg/m2 and did not accumulate upon weekly administration. The mean terminal elimination half-life of GSK923295 was 9–11 h. One patient with urothelial carcinoma experienced a durable partial response at the 250 mg/m2 dose level.
Conclusions
The novel CENP-E inhibitor, GSK923295, had dose-proportional pharmacokinetics and a low number of grade 3 or 4 adverse events. The observed incidence of myelosuppression and neuropathy was low. Further investigations may provide a more complete understanding of the potential for GSK923295 as an antiproliferative agent.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Milagrese MR, Carlson RO (2006) Development of new cancer therapeutic agents targeting mitosis. Expert Opin Investig Drugs 15:1411–1425
Wood KW, Lad L, Luo L, Qian X et al (2010) Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. PNAS 107(13):5839–5844
Yu U, Feng Y-M (2010) The role of kinesin family proteins in tumorigenesis and progression. Cancer 116:5150–5160
Wacker SA, Kapoor TM (2010) Targeting a kinetochore-associated motor protein to kill cancer cells. PNAS 107(13):5699–5700
Weaver BAA, Cleveland DW (2007) Aneuploidy: instigator and inhibitor of tumorigenesis. Cancer Res 67:10103–10105
Sutton D, Gilmartin AG et al (2007) A potent and selective inhibitor of the mitotic kinesin CENP-E (GSK923295A) demonstrates a novel mechanism of inhibiting tumor cell proliferation and shows activity against a broad panel of human tumor cell lines in vitro. GlaxoSmithKline, Collegeville, PA, Cytokinetics, South[abstract]. In: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 22–26 Oct 2007; San Francisco, CA. AACR Meeting Abstracts, Oct 2007; Philadelphia (PA) p 100 Abstract A111
Chua PR, Radhika R, Desai et al (2007), Differential response of tumor cell lines to inhibition of the mitotic checkpoint regulator and mitotic kinesin, CENP-E. [abstract]. In: AACR Meeting abstracts,-NCI-EORTC International conference: molecular targets and cancer therapeutics; 22–26 Oct 2007; San Francisco (CA) Abstract A114
Sutton D, Diamond M, Faucette L et al (2007) GSK923295A, a potent and selective CENP-E inhibitor, has broad spectrum activity against human tumor xenografts in nude mice [abstract]. In: Proceedings of the 98th annual meeting of the American association of cancer research; Apr 14–18 2007; Los Angeles, CA, Philadelphia (PA) Abstract 1522
Hu, Z, Mao, J-H, Huang, G et al (2009) A Systems analysis of mitotic apparatus inhibitors defines a response network for breast cancer. 32nd Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX. December, Poster Presentation
Guidance for Industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); July 2005
NCI Common Terminology Criteria for Adverse Events, Version 3, DCTD, NCI, NIH, DHHS, August 9, 2006
Simon R, Freilin B, Rubenstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for Phase I clinical trials in oncology. J Natl Cancer Inst 89:1138–1147
Plummer R, Ghielmini M, Calvert P et al (2002) Phase I and pharmacokinetic study of the new taxane analog BMS-18446 given weekly in patients with advanced malignancies. Clin Cancer Res 8:2788–2797
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2:205–216
Tas F, Eralp Y, Basaran M et al (2002) Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol (CCT) 25(4):371–379
Schwartz GK, Ilson D, Saltz L et al (2001) Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 19(7):1985–1992
Huszar D, Theoclitou ME, Skolnik J, Herbst R (2009) Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev 28:197–208
Jackson JR, Patrick DR, Dar MM et al (2007) Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 7:107–117
Dupont J, Bienvenu B, Aghajanian C et al (2004) Phase I and pharmacokinetic study of the novel oral cell cycle inhibitor Ro 31–7453 in patients with advanced solid tumors. J Clin Oncol 2(16):3366–3374
Johnson B, Sutton D, Fleming R et al (2009) Exploratory methods for assessment of therapeutic exposures and schedules of GSK923295A, a novel mitotic checkpoint inhibitor. 100th AACR Annual Meeting, April 18–22, Denver CO, Poster Presentation, Abstract 5452
Acknowledgments
We would like to thank the patients and families who participated in this trial as well as the study staff at the Phase I units of the University of Wisconsin, City of Hope Medical Center and Karmanos Cancer Center. We also thank Dr. Patricia LoRusso at the Karmanos Cancer Center for her input and contributions to the study, Ted Gonzalez and Dave Lundberg of GlaxoSmithKline for their expertise in data management and bioanalysis, respectively, and Dr. Guissou Dabiri for assistance in the preparation of this manuscript.
Conflict of interest
This study was sponsored by GlaxoSmithKline. V. Chung, E. I. Heath, W. R. Schelman and K. D. Holen were principal investigators who were involved with the conduct of the study at their respective institutions. K. M. Lynch and J. D. Botbyl were paid consultants for GlaxoSmithKline. T. A. Lampkin, B. M. Johnson and L. C. Kirby were employees of GlaxoSmithKline.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chung, V., Heath, E.I., Schelman, W.R. et al. First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. Cancer Chemother Pharmacol 69, 733–741 (2012). https://doi.org/10.1007/s00280-011-1756-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-011-1756-z